Recent Developments of Structure Based β-Secretase Inhibitors for Alzheimers Disease

Author(s): Aurn K. Ghosh, Nagaswamy Kumaragurubaran, Jordan Tang.

Journal Name: Current Topics in Medicinal Chemistry

Volume 5 , Issue 16 , 2005

Become EABM
Become Reviewer

Abstract:

The amyloid-β (Aβ) peptide is the principal components of the senile plaques found in the brains of patients with Alzheimers disease (AD). The poorly soluble 40-42 amino acid peptide, formed from the cleavage of the Ab precursor protein (APP) by two proteases, is believed to play a central role in the pathogenesis of AD. β-Secretase (memapsin 2, BACE1), a membrane-anchored aspartic protease, is responsible for the initial step of APP cleavage leading to the generation of Aβ. Identification and structural determination of β-secretase have established it to be a primary drug target for AD therapy and stimulated active studies on the inhibitors of this protease. Here we review more recent developments in the design and testing of structure-based β-secretase inhibitors.

Keywords: Alzheimer's disease, amyloid-β peptide, β-amyloid precursor protein, β-Secretase, Memapsin 2, aspartyl protease inhibitors, BACE-1, neurodegenerative disease, drug development

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 5
ISSUE: 16
Year: 2005
Page: [1609 - 1622]
Pages: 14
DOI: 10.2174/156802605775009711
Price: $58

Article Metrics

PDF: 3